We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 20.50 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 18.00 | 23.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 20.50 | GBX |
Summit Therapeutics (SUMM) Share Charts1 Year Summit Therapeutics Chart |
|
1 Month Summit Therapeutics Chart |
Intraday Summit Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/9/2024 | 17:29 | Summit - Climbing to new heights | 25,837 |
| 30/7/2018 | 20:00 | Summit Therapeutics (SUMM) One to Watch | 1 |
| 10/7/2018 | 12:28 | Summit Therapeutics (SUMM) One to Watch | - |
| 02/6/2018 | 19:07 | Time to Look at Summit Therapeutics (SUMM) | 1 |
| 12/11/2017 | 02:48 | Summit Therapeutics' View on Utrophin Modulation | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 13/9/2024 15:29 by football one maybe rightcautiousmoney26 Jul '24 - 16:19 - 25828 of 25834 hhhmmmmmm $100 dollar per share ??? |
Posted at 26/7/2024 15:19 by cautiousmoney $ 11.38well, the 7000 adr's well and truly out of the bottom drawer now :-)) good job i filled the yankee tax form in ! might be time to cash in or wait for the big takeover ?? hhhmmmmmm $100 dollar per share ??? |
Posted at 15/9/2021 10:10 by chrisatrdg I have finally Sold out did so last week with a profit margin after many years invested & have risked all on INFA - fingers crossed.PS I will still keep an eye on SUMM |
Posted at 09/2/2021 13:14 by chrisatrdg Following the above I posted:Chrisatrdg Posts: 2,155 Price: 0.00 Strong Buy RE: Next stop?Today 13:01 Hi EP - I de-risked in January leaving 1,400 shares in my non-ISA account & over the last 3-4 years have Sold some 75% of my shares & over that time achieved 'Break Even'.My 1,400 shares are now worth £11,374 (up 122.30%) & cannot Sell because of CGT limits. I realised my error in January & bought back in a few days after 1,445 shares now worth £11,739 (up 78.93%) in less than a month but are in a Stock ISA. I can understand your dilemma EP as I have been in the same position on two occasions & did not Sell at great cost to me. The sensible thing to do for me is to Sell today my ISA shares & pocket the money but who would have thought the shares would have gone up 24.89% yesterday & will this be repeated today. I remember talking to the Chief Scientific officer at a Summit AGM 2 years ago & he said that if Summit are successful with C-Diff the share price increase would be significant I guess double or treble & likely more if Summit go to market is my thinking now. I have e-mailed Summit this week on the issue of the trials & I am awaiting an answer but if the current share price is a blip down it will go back to where we started. I will await the opening bell with finger at the ready & based on my previous experiences should Sell (Third time lucky). Regards to all. |
Posted at 29/9/2020 11:47 by chrisatrdg Results Out YE 30th June 2020Summit Therapeutics Inc. (‘Summit’ Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2020 Cambridge, MA, September 29, 2020 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the second quarter and six months ended June 30, 2020. Ridinilazole for C. difficile Infection (‘CDI’) Summit published data from its Phase 2 clinical trial of ridinilazole evaluating the effects of a narrow-spectrum (ridinilazole) or broad-spectrum antibiotic (vancomycin) on intestinal bile acid profiles. This was the first study to demonstrate in humans the relationships between Clostridioides difficile antibiotic treatment choice and bile acid metabolism both during therapy and after treatment cessation. The results indicated that ridinilazole maintained an intestinal bile acid profile associated with a lowered risk of recurrence. The data were published in the American Journal of Physiology – Gastrointestinal and Liver Physiology. As of August 31, 2020, Summit had enrolled a total of 369 patients into its Phase 3 Ri-CoDIFy clinical trials of ridinilazole. Below is a table outlining the enrollment statistics by calendar quarter and for this past July and August since the opening of the trials in February 2019. Quarter Number of patients enrolled Cumulative Patients Enrolled Q1 2019 9 9 Q2 2019 21 30 Q3 2019 43 73 Q4 2019 78 151 Q1 2020 101 252 Q2 2020 73 325 July 2020 22 347 August 2020 22 369 Due to the uncertainties surrounding COVID-19, Summit is withdrawing public commentary on the timing of completion of the Phase 3 Ri-CoDIFy clinical trials. The Company plans to publicly update stakeholders quarterly as to enrollment status. The Ri-CoDIFy clinical trials aim to support application for marketing approval of the precision antibiotic ridinilazole in the United States and other territories and the goal of it being used as a first-line treatment for CDI by: testing for superiority over the current standard of care, vancomycin, in the primary endpoint of sustained clinical response at 30 days after treatment has ended; generating health economic data to support ridinilazole's commercial launch, when as and if approved by regulatory authorities; and undertaking microbiome and metabolome analysis that aims to show ridinilazole’s impact on the gut microbiome and bile acids composition BARDA is supporting the Phase 3 clinical trials and regulatory development of ridinilazole with a financial award of potential funding of up to $72.5 million. As of June 30, 2020, an aggregate of $46.6 million had been received. Discuva Platform Enterobacteriaceae DDS-04 compound series is a new class of precision antibiotics, with new mechanism of action, which is in lead optimization that acts via the novel bacterial target LolCDE with the potential to treat multidrug resistant infections caused by the Gram-negative bacteria Enterobacteriaceae. Gonorrhoea Based on results from recent preclinical studies, the DDS-01 series of antibiotics against Neisseria gonorrhoeae was determined not to have suitable qualities for further development as it had shown toxicity in animal studies and therefore, Summit is ceasing work on the gonorrhea program. The Company expects CARB-X will cover its remaining share of the work that has been funded under the award. Corporate Highlights Mr. Michael Donaldson was appointed as Chief Financial Officer in June 2020. Previously, Mr. Donaldson served as Vice President, Finance, and Corporate Controller for Goldfinch Bio, Inc. from 2018 to 2020 and Vice President, Finance, Corporate Controller and Assistant Treasurer at ARIAD Pharmaceuticals, Inc., which was acquired by Takeda, Inc. in 2017, from 2016 to 2017. Prior to that, he was the Corporate Controller for Hittite Microwave Corporation, which was acquired by Analog Devices in 2014. Mr. Donaldson spent the first 11 years of his career at PricewaterhouseCoope Dr. Jos Houbiers was promoted to Chief Medical Officer in July 2020. Dr Houbiers brings to Summit over 20 years of experience in pharmaceutical clinical development, where he’s implemented clinical development strategies, creative trial design and comprehensive medical safety monitoring across therapeutic areas, including functional urology, immunology and transplantation. He was most recently at Astellas, where he served in roles of increasing responsibility in clinical development from the Global Development hub, where he ended as Executive Medical Director and Group Head for the Medical Science Urology department. Dr. Houbiers received his MD from Leiden University Medical Center and PhD (immunology) and MSc in medicine from Leiden University. Ms. Ujjwala Mahatme was appointed as a Director in July 2020. Mr. Robert W. Duggan was appointed as Chief Executive Officer and Dr. Ventzislav Stefanov was appointed Executive Vice President and President of Discuva, the Company's discovery engine employing 14 people, in April 2020. Mr. Glyn Edwards stepped down as Chief Executive Officer in April 2020 and from the Board of Directors in June 2020. Summit has redomiciled to the United States, effective September 18, 2020. COVID-19 In light of the ongoing COVID-19 pandemic, Summit's employees continue to work remotely, enabling the majority of day to day business operations to continue. Summit's own laboratory facilities have begun to reopen to resume work on key projects; site access by staff is being monitored closely and is limited to ensure the safety of Summit researchers. There continues to be a negative impact on patient enrollment into the Ri-CoDIFy clinical trials. We are working to implement a number of initiatives and considering alternative courses of action to mitigate the impact of the COVID-19 pandemic on our clinical trials, although there can be no assurance that such actions will be successful. Financial Highlights Cash and cash equivalents at June 30, 2020, of $36.4 million compared to $63.8 million at December 31, 2019. The Company's existing cash and cash equivalents and committed external funding are expected to be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements through January 31, 2021. The Principal shareholder of the Company, Mr. Robert W. Duggan, has given his intention to the Board of Directors to participate in a future fundraise as required in order to support the Company with its clinical operations and planned research and development efforts. Loss for the six months ended June 30, 2020, of $21.6 million compared to a loss of $13.7 million for the six months ended June 30, 2019. |
Posted at 28/1/2020 10:36 by waterloo01 From HLWhat is happening? The Board of Summit Therapeutics plc has announced proposals to cancel the Company’s ordinary shares from trading on AIM (Alternative Investment Market). It is expected that the Company’s shares will be delisted with effect from the 7am on 24 February 2020. If the Delisting is approved at the shareholder Meeting Summit Therapeutics will be offering shareholders the opportunity to convert their ordinary shares into American depositary receipts (ADRs). ADRs are a form of stock traded in the US that represent a number of shares in a foreign Company. If approved we will write to you after the shareholder Meeting to inform you of the terms of the conversion. Why is this happening? “The AIM Delisting reflects the increasing focus of the Company’s business operations on the United States.” (Source: shareholder announcement, 6 December 2019) What action do I need to take? For the delisting to become effective, it must be approved at a General Meeting to be held on Monday 23 December 2019. Under AIM Rules, such a withdrawal resolution requires the consent of not less than 75% of votes cast by shareholders voting on the resolutions at the General Meeting. If you would like to submit a vote for or against the resolution to delist the shares, please provide us with your voting instruction by noon on Wednesday 18 December 2019 by clicking on your Fund & Share Account in the ‘My Accounts’ section of our website. Please then select the dark blue Corporate Actions Icon alongside your Summit Therapeutics plc shares and follow the online instructions provided. If you wish to sell your holding before the proposed listing cancellation you must do so before 4.30pm on Friday 21 February 2020. The trade will be placed in accordance with our terms and conditions and subject to the standard Stockbrokers commission rates. To sell these shares please phone us on 0117 980 9800 or you can place a trade online. Please note that if the cash consideration of a sale does not exceed the commission payable then the sale will not be executed. Please note that although Hargreaves Lansdown will endeavor to sell your shares it may not be possible to sell all, or even any, of your shares if a market for the shares no longer exists. If you dispose of your holding before shareholder approval has been granted you do so at your own risk. If you wish to maintain your holding you need take no action. You should note that following the cancellation you may have difficulty selling this investment at a reasonable price and, in some circumstances, it may be impossible to sell it at any price. Important information for holders of Summit Therapeutics plc shares within a Stocks & shares ISA Please note under HMRC rules unlisted shares and ADS’ are not eligible to be held within a Stocks & shares ISA. As a result, if the delisting become effective, any holding of Summit Therapeutics plc shares within a Stocks & shares ISA will need to be removed within 30 days of the effective date of the delisting. |
Posted at 07/10/2019 12:06 by someuwin Summit Therapeutics plc Summit Therapeutics Reports New Data From Phase 2 Clinical Trial Connecting Ridinilazole's Microbiome...07/10/2019 12:00pm UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Therapeutics Reports New Data from Phase 2 Clinical Trial Connecting Ridinilazole's Microbiome Preservation to Improved Clinical Outcomes for Patients with C. difficile Infection -- Data Presented at ID Week 2019 Oxford, UK, and Cambridge, MA, US, 7 October 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced the presentation of new data that explain the link between two key findings in the Company's Phase 2 clinical trial of ridinilazole for C. difficile infection ('CDI'): -- Ridinilazole demonstrated superior efficacy compared to vancomycin, driven by a 60% lower recurrence rate. -- Ridinilazole preserved the diversity of the gut microbiome. Researchers at Tufts University, collaborating with Summit, showed that these findings are connected mechanistically by bile acids, part of the 'metabolome' of active chemicals made or modified by gut bacteria. Bile acids exist in different forms that can either favour or block the regrowth of C. difficile after treatment. Vancomycin kills bacteria that turn pro-C. difficile bile acids into anti-C. difficile bile acids -- leaving an adverse ratio of pro- and anti-growth chemicals that favours the regrowth of C. difficile and the recurrence of C. difficile infection. By contrast, ridinilazole leaves these bacteria unharmed, allowing them to keep converting pro-C. difficile bile acids into anti-C. difficile bile acids, maintaining a positive chemical balance that prevents C. difficile recurrence. "The damaging effect of broad-spectrum antibiotics in the treatment of CDI is far-reaching from the make-up and function of the gut microbiome through the poor clinical outcomes seen in one third of patients, driven by a high rate of disease recurrence," said Dr David Roblin, President of R&D of Summit. "Ridinilazole has the potential to be a targeted CDI treatment that could result in significantly better patient outcomes for the over half million US patients per year who have an episode of CDI. These latest data help to put the science behind the function of a healthy microbiome into context and highlight its importance in sustaining CDI cures." The Phase 2 clinical trial enrolled 100 patients, half of whom received ridinilazole and the other half vancomycin. For both groups, there was a higher ratio of pro-C. difficile to anti C.-difficile bile acids at the start of treatment. This was expected, as patients who get CDI have perturbed microbiomes. However, during treatment, the proportion of anti-C. difficile bile acids increased in patients treated with ridinilazole, whereas patients treated with vancomycin initially showed decreases in anti-C. difficile bile acids and had stools dominated by pro-C. difficile bile acids. By the end of treatment, ridinilazole-treated patients' bile acid ratios returned towards a healthy, non-CDI state. These results support the data from the Phase 2 clinical trial, in which patients receiving ridinilazole showed a statistically significant improvement in sustained clinical responses. Copies of the two poster presentations are available in the Publications section of Summit's website, www.summitplc.com. |
Posted at 17/7/2019 11:09 by kirk 6 Summit Therapeutics plc Summit Highlighted Potential Of Smt-571 To Combat The Rising Global Health Threat Of Gonorrhoea At St...Source: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Highlighted Potential of SMT-571 to Combat the Rising Global Health Threat of Gonorrhoea at STI & HIV World Congress Oxford, UK, and Cambridge, MA, US, 17 July 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat all gonorrhoea, including multi-drug and extensively-drug resistant strains, in a poster presentation at the STI & HIV World Congress in Vancouver, Canada. "The problem of gonorrhoea resistance is very concerning, and if nothing is done, physicians could see more and more cases of untreatable disease, " said Dr David Roblin, President of R&D of Summit. "As shown by the preclinical data presented, our gonorrhoea-targeted new class antibiotic, SMT-571, has the potential to overcome known resistance mechanisms across global isolates, including multi- and extensively-drug resistant strains. Further, there is a clear need for new gonorrhoea treatment options that would allow ceftriaxone to be reserved for the multitude of other serious infections that rely on its potency." Infections caused by the bacteria Neisseria gonorrhoeae are a growing global healthcare problem, with an estimated 78 million new cases globally per year. Infection rates continue to rise sharply as highlighted by the Centers for Disease Control and Prevention ('CDC'), which reported a 19% increase in US gonorrhoea cases in 2017, and Public Health England, which reported a 26% increase in the UK in 2018. Of great concern is the increase in resistance towards the current standard of care treatment for gonorrhoea, a combination of the broad-spectrum antibiotics, azithromycin and ceftriaxone. N. gonorrhoeae resistance rates to azithromycin are 4.4% and rising, and there is an emergence of resistance to ceftriaxone in these same strains, which are referred to as cases of 'super gonorrhoea.' Summit's poster featured preclinical data showing SMT-571 to be highly potent against 262 clinical strains of N. gonorrhoeae. This comprehensive panel of gonorrhoea strains, obtained from 1991 to 2018, was selected to be geographically and genetically diverse and include strains that are multi- and extensively-drug resistant. SMT-571 had a minimum inhibitory concentration range of 0.064 mg/L to 0.125 mg/L against the strains, including those with reduced susceptibility to ceftriaxone. Significantly, SMT-571 did not show cross-resistance with any antibiotic currently or previously used to treat gonorrhoea infections. A copy of the poster is available on the Company's website: https://www.globenew |
Posted at 18/6/2019 11:08 by kirk 6 Summit Therapeutics plc Increased Barda Award And Option ExerciseSource: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ('Summit' or the 'Company') Summit Announces BARDA Increases Award for Ridinilazole Clinical and Regulatory Development to up to $63.7 Million and Exercises Next Contract Option -- Summit Awarded $9.6M under Next Contract Option -- Total Committed BARDA Funding Now $53.6 Million Oxford, UK, and Cambridge, MA, US, 18 June 2019 -- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, today announces that the Biomedical Advanced Research and Development Authority ('BARDA') has increased the total value of its award for the clinical and regulatory development of Summit's precision antibiotic ridinilazole for the treatment of C. difficile infection ('CDI') to up to $63.7 million. Under this award, BARDA has opted to exercise the next contract option for $9.6 million, which will support patient enrolment and dosing in the ongoing Phase 3 clinical trials of ridinilazole. "The funding from BARDA is a testament to the promise of ridinilazole to address an important public health need in CDI. Through our ongoing landmark Phase 3 clinical programme, we aim to show that our microbiome preserving antibiotic is superior in sustaining cures compared to the current standard of care and so has the potential to be the front-line treatment option for patients with CDI," said Mr Glyn Edwards, Chief Executive Officer of Summit. "We are pleased with the excellent working relationship that has been formed between us over the last two years and thank BARDA for its continuing support of ridinilazole." The total committed funding from the BARDA award under Contract No. HHS0100201700014C is now $53.6 million, with one final option remaining. The final option provides funding support for potential applications for marketing approvals of ridinilazole. The BARDA contract provides for a cost-sharing arrangement with the committed funding drawn down over a specified development period. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR). About C. difficile Infection C. difficile infection is a serious healthcare threat in hospitals, long-term care homes and increasingly in the wider community with over one million estimated cases of CDI annually in the United States and Europe. CDI is caused by an infection of the colon by the bacterium C. difficile, which produces toxins that cause inflammation and severe diarrhoea, and in the most serious cases can be fatal. Patients typically develop CDI following the use of broad-spectrum antibiotics that can cause widespread damage to the natural gastrointestinal (gut) flora and allow overgrowth of C. difficile bacteria. The vast majority of patients are treated with broad-spectrum antibiotics, which cause further damage to the gut flora and are associated with high rates of recurrent disease. Reducing disease recurrence is the key clinical issue in CDI as repeat episodes are typically more severe and associated with an increase in mortality rates and healthcare costs. A study estimated that the total costs attributable to the management of CDI were approximately $6.3 billion per year in the United States. About Ridinilazole Ridinilazole is an oral small molecule new mechanism antibiotic that is designed to selectively kill C. difficile, thereby preserving patients' protective gut microbiome and leading to sustained CDI cures. In a Phase 2 proof of concept trial in CDI patients, ridinilazole showed statistical superiority in sustained clinical response ('SCR') rates compared to the standard of care, vancomycin. In that trial, SCR was defined as clinical cure at end of treatment and no recurrence of CDI within 30 days of the end of therapy. Ridinilazole was also shown to be highly preserving of the gut microbiome in the Phase 2 proof of concept trial, which was believed to be the reason for the improved clinical outcome for the ridinilazole-treated patients. In addition, ridinilazole preserved the gut microbiome to a greater extent than the marketed narrow-spectrum antibiotic fidaxomicin in an exploratory Phase 2 clinical trial. Ridinilazole has received Qualified Infectious Disease Product ('QIDP') designation and has been granted Fast Track designation by the US Food and Drug Administration. The QIDP incentives are provided through the US GAIN Act and include a potential extension of marketing exclusivity for an additional five years upon FDA approval. About the Contract with BARDA This project has been funded in whole or in part with federal funds from the Biomedical Advanced Research and Development Authority, a component of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, under contract number HHS0100201700014C. About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. Contacts Summit Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500 Phil Walker / Dominic Wilson MSL Group (US) Tel: +1 781 684 6557 mailto:summit@mslgro |
Posted at 15/4/2019 06:20 by kirk 6 Released .....Summit Therapeutics plc Summit Presents In Vivo Proof Of Concept Data For New Mechanism Antibiotics Targeting Enterobacteriac...So |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
